B55.0 Visceral leishmaniasis

Name of the Condition

• Visceral leishmaniasis

Summary

Visceral leishmaniasis is a severe, systemic parasitic infection caused by Leishmania protozoa. It primarily affects internal organs such as the spleen, liver, and bone marrow, leading to progressive deterioration of organ function. The disease is often referred to as kala-azar and can be fatal if untreated, particularly in immunocompromised individuals.

Causes

Visceral leishmaniasis is caused by Leishmania donovani, Leishmania infantum, or related species. Transmission occurs through the bite of infected female sandflies, which introduce the parasites into the bloodstream. The parasites then invade and replicate within macrophages, spreading to visceral organs and causing widespread inflammation and tissue damage.

Risk Factors

• Residence in or travel to endemic regions, including parts of Asia, Africa, Latin America, and the Mediterranean.
• Immunocompromised states, such as HIV/AIDS, organ transplantation, or chemotherapy.
• Malnutrition or other conditions that impair immune function.
• Exposure to sandfly habitats, such as rural or tropical environments.

Symptoms

• Persistent fever, often with a double daily peak.
• Significant weight loss and muscle wasting.
• Enlarged spleen (splenomegaly) and liver (hepatomegaly).
• Anemia, leading to fatigue and weakness.
• Abdominal distension and discomfort.
• Bleeding tendencies, such as nosebleeds or bruising.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. Blood tests may show anemia, leukopenia, or elevated liver enzymes. Parasite detection via bone marrow, spleen, or lymph node aspiration is confirmatory. Serological tests (e.g., rK39) or molecular methods (PCR) may also be used. Imaging studies, such as ultrasound, can assess organ enlargement.

Treatment Options

Treatment depends on disease severity and regional guidelines. First-line therapies often include liposomal amphotericin B, miltefosine, or paromomycin. Combination regimens may be used for resistance or severe cases. Supportive care, such as blood transfusions or nutritional support, may be necessary for complications.

Prognosis and Follow-Up

With prompt and appropriate treatment, prognosis is generally good, though relapse can occur. Untreated visceral leishmaniasis has a high mortality rate, especially in immunocompromised patients. Follow-up includes monitoring for treatment response, recurrence, and organ function recovery. Long-term surveillance may be required for high-risk individuals.

Complications

• Severe anemia or thrombocytopenia leading to bleeding.
• Secondary bacterial infections due to immunosuppression.
• Organ failure (e.g., liver or kidney) in advanced cases.
• Post-kala-azar dermal leishmaniasis, a skin condition occurring after treatment.

Lifestyle & Prevention

• Avoid sandfly bites by using insect repellent, bed nets, and protective clothing in endemic areas.
• Control sandfly breeding sites by eliminating standing water and waste.
• Seek early medical care for symptoms if traveling to or living in high-risk regions.
• Maintain good nutrition and immune health to reduce susceptibility.

When to Seek Professional Help

Seek immediate medical attention if experiencing persistent fever, unexplained weight loss, or abdominal swelling, especially after travel to endemic areas. Prompt diagnosis and treatment are critical to prevent life-threatening complications.

Tips for Medical Coders

Document the specific Leishmania species if known, as it may impact coding specificity. Include details on organ involvement (e.g., splenic, hepatic) and treatment response. Note any immunocompromised status or comorbidities, as these may affect code assignment. Ensure documentation supports the diagnosis and aligns with clinical guidelines for visceral leishmaniasis.